Imara announces completion of patient enrollment in ardent phase 2b clinical trial of imr-687 (tovinontrine) for sickle cell disease

Interim analysis expected in fourth quarter of 2021 and primary endpoint readout now expected in first quarter of 2022 interim analysis expected in fourth quarter of 2021 and primary endpoint readout now expected in first quarter of 2022
ELVN Ratings Summary
ELVN Quant Ranking